Validation of cerebral blood flow-related biomarkers for neurodegenerative disease at an early stage

Validation of cerebral blood flow-related biomarkers for neurodegenerative disease at an early stage - MemoLife

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49623

Enrollment

355

Registered

2020-11-26

Start date

2021-09-01

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Alzheimer's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers - minimum age of 50 years (which is the minimum age in the Lifelines/ImaLife population); - willingness to cooperate and sign written informed consent; - no prior history of neurologic or significant psychiatric illness. Patients: - minimum age of 50 years - diagnosis of MCI or A.D. - People with AD diagnosis: MMSE score between 18 - 26 - willingness to cooperate and sign written informed consent; - no prior history of significant psychiatric illness or cardiovascular disease

Exclusion criteria

Exclusion criteria: - a diagnosis of vascular disorder; - (other) neurological conditions; - contra-indications for MRI scanning (e.g., metal implants, claustrophobia, cardiac pacemaker, brain surgery); - absence of signed informed consent form; - the refusal to be informed about an unforeseen clinical finding.

Design outcomes

Primary

Measure	Time frame
Main study parameters entail blood flow-related measures such as cerebral blood flow, cerebral blood volume, etc., and other imaging-derived parameters. Non-imaging parameters include cognitive measures and other variables such as clinical information, sociodemographic factors, and lifestyle factors. Finally, the MR images will serve as input for the DCNN risk-detection model and will be augmented with the non-imaging parameters.	—

Measure

Time frame

Main study parameters entail blood flow-related measures such as cerebral blood flow, cerebral blood volume, etc., and other imaging-derived parameters. Non-imaging parameters include cognitive measures and other variables such as clinical information, sociodemographic factors, and lifestyle factors. Finally, the MR images will serve as input for the DCNN risk-detection model and will be augmented with the non-imaging parameters.

—

Countries

Netherlands

Outcome results